Eli Lilly has announced promising results from their latest research on a new GLP-1 pill, marking a significant advancement in diabetes treatment. The pharmaceutical company revealed that this oral medication demonstrated substantial benefits in managing blood sugar levels in individuals with Type 2 diabetes. The GLP-1 pill is designed to improve patient adherence due to its convenient oral form, compared to traditional injectable treatments. Eli Lilly’s data indicates that patients experienced reduced glucose levels and greater ease in managing their condition. This breakthrough has the potential to transform diabetes care for millions worldwide, providing a simpler and effective treatment option. The promising results highlight Eli Lilly’s commitment to innovation in the pharmaceutical industry, pushing forward the boundaries of diabetes management solutions.
ABC NewsNew data shows rental market at breaking point for young South Aussies
April 30, 2026
The rental market in South Australia has reached a critical juncture, with new data revealing that only five homes are considered affordable for young residents.